Baqsimi (glucagon) is a prescription drug that’s used to help treat severely low blood sugar episodes in people with diabetes. Baqsimi can cause side effects that range from mild to serious. Examples ...

The Food and Drug Administration (FDA) has approved Baqsimi (glucagon; Eli Lilly) nasal powder for the treatment of severe hypoglycemia in patients with diabetes aged 4 years and older. The Food and ...

Nasal glucagon is seen as a game-changing delivery method to replace the multistep system of mixing powder and liquid with a simple, 1-step spray. The FDA Wednesday approved Eli Lilly & Co.’s nasal ...

School personnel should soon be allowed to administer a new nasal spray used to treat severe hypoglycemia. In 2019, the Food and Drug Administration approved the use of Baqsimi nasal powder, the first ...

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an ...

Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of ...

The US Food and Drug Administration (FDA) has approved the first nasally administered glucagon product (Baqsimi, Eli Lilly and Co) for the treatment of severe hypoglycemia for patients aged 4 years or ...

Isabel Casimiro, MD, PhD, is an endocrinologist at the University of Chicago in Illinois. As a physician-scientist in molecular biology, she uses her research on diabetes, lipid disorders, ...

(RTTNews) - Pharma major Eli Lilly and Company (LLY) said on Monday that it has inked a deal with Amphastar Pharmaceuticals, Inc. (AMPH), to divest BAQSIMI, the dry nasal spray to treat very low blood ...

For this use, doctors may prescribe Baqsimi to adults as well as children 4 years and older. Both type 1 and type 2 diabetes are long-term conditions. If you and your doctor agree that Baqsimi is safe ...